HORIZON EUROPE
Europeo
ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to the following expected outcomes:
All players along the health care value chain are provided with new knowledge for a better understanding of the links (e.g. causalities) between infectious diseases (IDs) and non-communicable diseases (NCDs) and comorbidities, including knowledge on host risk factors that impact the development of disease progression for NCDs and/or IDs.Researchers and clinicians are provided with a robust evidence base that will contribute to the development of new or improved tools to diagnose and prevent the development and aggravation of non-communicable disease(s) as well as early treatment and management of patients suffering from co-morbidities following an infectious disease.Healthcare practitioners have access to knowledge to guide them on preventive measures, on early identification of diseases onset and of those patients at ri...
ver más
ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to the following expected outcomes:
All players along the health care value chain are provided with new knowledge for a better understanding of the links (e.g. causalities) between infectious diseases (IDs) and non-communicable diseases (NCDs) and comorbidities, including knowledge on host risk factors that impact the development of disease progression for NCDs and/or IDs.Researchers and clinicians are provided with a robust evidence base that will contribute to the development of new or improved tools to diagnose and prevent the development and aggravation of non-communicable disease(s) as well as early treatment and management of patients suffering from co-morbidities following an infectious disease.Healthcare practitioners have access to knowledge to guide them on preventive measures, on early identification of diseases onset and of those patients at risk of developing severe disease progression, and on the optimal treatment of patients. When NCDs are related to infectious diseases with pandemic potential, healthcare practitioners will be provided with new evidence to help them make informed decision on the management of the diseases in the future. Public health authorities will be better prepared to issue targeted recommendations linked or not to the use of specific medical countermeasures in crisis times.
Scope:Increasing evidence suggests that several infections might influence the development of many non-communicable diseases (e.g. multiple sclerosis, Alzheimer, post-covid-19 condition[1]), or that NCD may be influenced by concurrent presence in the same individual of one (or more) infections. On the other hand, NCDs might represent risk factors for IDs.
The proposals are expected to elucidate and provide a better understanding of causative links between infections and non-communicable diseases onsets, and/or the impact of infections on the exacerbation of existing NCDs or vice versa, in children and/or adults. The analysis of genetics, immune status, immune or inflammatory responses, microbiome, lifestyle and/or other relevant factors (e.g. differences in age, sex/gender, vaccination status, ethnicity) should be integrated to get information for prevention, early diagnosis, risk factors, and to better understand causative links as well as the progression of those non-communicable diseases.
In determining the connection between one or multiple concomitant infection(s) and the development of non-communicable disease(s), the proposals might address any infection including those with pandemic potential (viral, bacterial, or fungal) with non-communicable diseases of major importance. Research on cancer is excluded as it will be covered by the Mission on Cancer.
Special attention should be given to vulnerable individuals, such as those with known existing preconditions.
Preclinical research, observational studies and/or clinical studies can be considered for this topic. Proposals could include patient follow-up to identify conditions that may appear only after a patient has recovered from the infectious disease. Those proposals including clinical evaluation should give a sound feasibility assessment, provide details of the methodology, including an appropriate patient selection and realistic recruitment plans, justified by available publications and/or preliminary results.
The applicants are encouraged to incorporate artificial intelligence (AI) tools that enable advanced quality data analysis and for assessing and predicting the risk of developing a disease and/or the risk of disease progression/severity where relevant.
Projects funded under this topic that focus on COVID-19 and post COVID-19 condition (also known as long-COVID) are strongly encouraged to collaborate and build links with (one of) the relevant EU-funded projects, such as ORCHESTRA[2]. They should also pay special attention and link to the newly established European COVID-19 data sharing platform[3].
Applicants envisaging to include clinical studies should provide details of their clinical studies in the dedicated annex using the template provided in the submission system. See definition of clinical studies in the introduction to this work programme part.
[1] https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1
[2] https://orchestra-cohort.eu/
[3] https://www.covid19dataportal.org/
ver menos
Características del consorcio
:
La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Características del Proyecto
Gastos relacionados con el personal que trabaja directamente en el proyecto basado en las horas efectivas dedicadas, basado en el coste empresa y ratios fijos para determinados empleados como los dueños de la compañía.
Pagos a terceros externos para realizar tareas específicas que no pueden ser realizadas por los beneficiarios del proyecto.
Incluyen la adquisición de equipos, amortizaciones, material, licencias u otros bienes y servicios necesarios para la ejecución del proyecto
Gastos diversos como costes financieros, certificados de auditoría o participación en eventos no cubiertos por otras categorías
Gastos generales no asignables directamente al proyecto (como electricidad, alquiler u oficina), calculados como un 25% fijo sobre los costes directos elegibles (excepto subcontratación).
Características de la financiación
Para el presupuesto subvencionable la intensidad de la ayuda en formato fondo perdido podrá alcanzar como minimo un 100%.
Información adicional de la convocatoria
Otras ventajas
